Tissue treatments with adipocyte cells

• US 7,767,452 B2
• Filed: 02/28/2007
• Issued: 08/03/2010
• Est. Priority Date: 02/20/1997
• Status: Expired due to Fees

• Current Assignee: Don A. Kleinsek
• Original Assignee: Don A. Kleinsek
• Inventors: Kleinsek, Don A.
• Primary Examiner(s): Weber; Jon P
• Assistant Examiner(s): SCHUBERG, LAURA J
• Application Number:
  US11/711,921
• Publication Number:
  US 20070154461A1
• Time in Patent Office: 1,252 Days
• Field of Search: None
• US Class Current: 435/366
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/35 Fat tissue; Adipocytes; Stromal cells; Connective tissues adipose-derived stem cells A61K35/28; collagen A61K38/39
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Abstract

Certain embodiments here in are directed to a method of treating a tissue associated with a defect in a human including wrinkles, rhytids, depressed scar, cutaneous depressions, stretch marks, hyperplasia of the lip, nasolabial fold, melolabial fold, scarring from acne vulgaris, and post-rhinoplasty irregularity. The tissue defect may be treated by introducing a plurality of in vitro cultured autologous fibroblast cells at or proximal to the defect area of the patient'"'"'s tissue. The autologous fibroblast cells may have been cultured in vitro to expand the number of fibroblast cells in at least one medium that comprises autologous serum. The autologous fibroblast cell cultures may be derived from connective tissue, dermal, fascial fibroblasts, papillary fibroblasts, and/or reticular fibroblasts.

Claims

1. A method of treating a tissue associated with a defect in a patient using autologous materials derived from the patient, the method comprising:

introducing a plurality of autologous adipose cells to the tissue at, or proximal to, the defect of the patient after the plurality of autologous adipose cells have been cultured in vitro to expand the number of adipocyte cells in at least one medium that comprises autologous serum.

2. The method of claim 1 wherein extracellular matrix produced in vitro by the autologous adipose cells is introduced into the patient in association with the plurality of autologous adipose cells.

3. The method of claim 1 wherein the adipose cells comprise pre-adipocytes.

4. The method of claim 1 wherein the adipose cells comprise adipocytes.

5. The method of claim 1 wherein the adipose cells comprise nondifferentiated mesenchymal cells.

6. The method of claim 1 wherein fibronectin is introduced into the patient in association with the plurality of autologous adipose cells.

7. The method of claim 1 wherein collagen or modified collagen is introduced into the patient in association with the plurality of autologous adipose cells.

8. The method of claim 1 wherein hyaluronic acid is introduced into the patient in association with the plurality of autologous adipose cells.

9. The method of claim 1 wherein the introduction of the adipose cells into the patient comprises a method chosen from injection, engraftment, engraftment by threading, and direct placement.

10. The method of claim 1 wherein the tissue comprises a member of the group consisting of lower dermis, middle dermis, upper dermis, and skin subcutaneous region.

11. The method of claim 1 wherein the tissue comprises muscle tissue.

12. The method of claim 1 wherein the patient is human.

13. The method of claim 1, wherein the tissue is associated with a defect chosen from the group consisting of wrinkles, rhytids, depressed scar, cutaneous depressions, stretch marks, hyperplasia of the lip, nasolabial fold, melolabial fold, scarring from acne vulgaris, dermal, subcutaneous, skin defect, and post-rhinoplasty irregularity.

14. The method of claim 1 wherein the in vitro cultured cells are introduced into the patient in a mixture with a filler material, wherein the filler material, prior to mixing with the cells, comprises a member of the group consisting of collagen, fibronectin, fibrillin, laminin, elastin, glycosaminoglycan, exogenous extracellular matrix, whole extracellular matrix, and autologous extracellular matrix.

15. A method of treating a tissue associated with a defect in a patient, the method comprising:

introducing a plurality of isolated adipose cells to treat the defect of the patient after the plurality of adipose cells have been isolated in vitro.

16. The method of claim 15 wherein the tissue is associated with a defect chosen from the group consisting of wrinkles, rhytids, depressed scar, cutaneous depressions, stretch marks, hyperplasia of the lip, nasolabial fold, melolabial fold, scarring from acne vulgaris, dermal, subcutaneous, skin defect, and post-rhinoplasty irregularity.

17. The method of claim 15 wherein the cultured adipose cells are expanded in vitro.

18. The method of claim 15 wherein the cells are introduced into the patient in a mixture with a filler material, wherein the filler material, prior to mixing with the cells, comprises a member of the group consisting of collagen, fibronectin, fibrillin, laminin, elastin, glycosaminoglycan, exogenous extracellular matrix, whole extracellular matrix, and autologous extracellular matrix.

19. The method of claim 15 wherein the adipose cells comprise adipocytes.

20. The method of claim 15 wherein the adipose cells comprise pre- adipocytes.

21. The method of claim 15 wherein the adipose cells comprise undifferentiated mesenchymal cells.

22. The method of claim 15 wherein the adipose cells have been cultured in vitro to expand the number of adipocyte cells in at least one medium that comprises autologous serum.

23. The method of claim 15 wherein the adipose cells are allogeneic.

24. The method of claim 15 wherein the patient is human.

25. The method of claim 15 wherein the cells are autologous.

26. The method of claim 15 wherein the cells are placed at, or proximal to, the defect.

27. The method of claim 15 wherein the cells are in a suspension.